Microsoft word - status of mrl procedure - emea-cvmp-765-99
Veterinary Medicines and InspectionsSTATUS OF MRL PROCEDURES MRL assessments in the context of Council Regulation (EEC) No 2377/90
Background and legislative framework In order to protect the safety of the consumer of foodstuffs of animal origin, one of the most important principles laid down in the European Union (EU) legislation with regard to the marketing authorisation of veterinary medicines is that foodstuffs obtained from animals treated with veterinary medicinal products must not contain residues which might constitute a health hazard for the consumer. Before a veterinary medicinal product intended for food producing animals can be authorised in the EU, all pharmacologically active substances contained in the product have to undergo a safety and residues evaluation, and have to be included in Annex I, II, or III of Council Regulation (EEC) No 2377/901. The safety and residue evaluation in accordance with Regulation 2377/90 is carried out by the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMEA), supported by safety and residues experts, upon receipt of a valid application for the establishment of maximum residue limits (MRLs). Substances for which definitive MRLs have been established are included in Annex I of Regulation 2377/90. MRLs can be proposed as provisional, if all aspects are not yet fully addressed. In this case the substance is inserted in Annex III with an expiry date defining for the termination of the provisional status. However, no provisional MRLs can be proposed, if major issues with regard to safety remain to be addressed, as it must be assured that residues at the proposed levels do not present a hazard to the health of the consumer. Only, once the applicant has satisfactorily answered the outstanding questions, the substance can be included in Annex I. These questions are likely to relate to the provision of fully validated analytical methods. Where, following the evaluation, it appears that it is not necessary for the protection of public health to establish MRLs, such substance is included in Annex II. It should be noted that an entry in Annex II is not equivalent to the status “generally recognised as safe”. In fact only a sub-group of Annex II substances do fall under this category. For further details on the assessment of a substance you are advised to consult the MRL Summary report of the substances concerned. Please also note that Annex II comprises a specific entry, which provides that certain substances approved in the EU as food additives with a valid E-number are considered included in Annex II without listing the substances specifically. Relevant substances falling under these provisions are e.g. vitamin C, citric acid or several sodium and potassium salts, and these substances are only mentioned in the enclosed list if an MRL application was submitted.
1 Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits for veterinary medicinal products in foodstuffs of animal origin (O.J. NO L 224, 18.8.1990, p.1), as amended by Commission Regulation (EEC) No 762/92 (O.J. No. L 83, 28.3.1992, p.14), Council Regulation (EC) No 434/97 (O.J. No L 67, 7.3.1997, p. 1), and Council Regulation (EC) No 1308/99 (O.J. L 156, 23.6.1999, p.1) Public
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 47
E-mail: mail@emea.europa.eu. www.emea.europa.eu
EMEA 2006 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged
A safety and residue evaluation may also result in the recommendation to include a substance in Annex IV of Regulation 2377/90, which means that the substance is prohibited from use in veterinary medicinal products for food producing animals. Another conclusion may be that due to the deficiencies of the data provided, no recommendation for inclusion in any of the annexes could be made; the net result in the latter case is the same as an inclusion in Annex IV, as no medicinal product containing such a substance can be authorised for food producing animals in the EU. During the period from 1992 to January 2005 over 700 “old” substances were reviewed and applications concerning 58 “new” substances and 87 extensions and modifications have been submitted to the CVMP; MRLs recommendations for inclusion in Annex, I, II or III were made for 645 substances in total. 115 substances were recommended for inclusion in Annex I of Regulation 2377/90, 513 in Annex II and 6 remain currently in Annex III. For 11 substances it was considered that their residues, at whatever limit, in foodstuffs of animal origin constitute a hazard to the health of the consumer, and they have been placed in Annex IV. For 40 substances, the CVMP was unable to make a recommendation for inclusion in any of the annexes and for further 57 substances the applicants withdrew their applications after the receipt of the list of questions. Procedure for MRL opinions Following the evaluation of an MRL application the CVMP issues an opinion which includes the recommendation regarding the establishment of MRLs for the substances considered and a Summary Opinion is published on the EMEA website (http://www.emea.eu.int/index/indexv1.htm). On the basis of the scientific recommendation of the CVMP for inclusion of a substance in Annex I, II, III or IV of Regulation 2377/90, the Commission prepares a draft regulation amending the respective Annex(es) accordingly. Any such Regulation requires a favourable opinion by qualified majority of the EU Member States, before the European Commission can adopt it. Once adopted, the European Commission publishes the Regulation amending the annexes of Regulation 2377/90 in the Official Journal of the European Communities. Following this publication the EMEA publishes the CVMP Summary Reports on the EMEA website: http://www.emea.eu.int/index/indexv1.htm. The European Commission services also provides access to all adopted Regulations amending the annexes of Regulation 2377/90 (http://europa.eu.int/eur-lex/) and a non-official consolidated list of the annexes of the Regulation listing all MRLs established, on the following web-site: (http://pharmacos.eudra.org/F2/mrl/index.htm). Substances with MRLs assessments in the EU Attached is an alphabetical list of all substances included in Annex I, II, III or IV of Regulation 2377/90 with the indication of the respective annex and the number of the Regulation which established these MRLs. In addition, the list includes substances for which MRL recommendations have been made by the CVMP and are now undergoing the decision-making procedure by the European Commission . The list also includes the substances for which the CVMP concluded that due to insufficient data provided a recommendation for inclusion of the substance in Annex I, II, III of Regulation 2377/90 could not be made.
Any enquiries regarding this connection may be directed to the attention of Dr Kornelia Grein, Head of
Sector (Safety of Veterinary Medicines) at the EMEA, 7 Westferry Circus, Canary Wharf, London E14
4HB, telephone +44 20 7 418 8432; email: kornelia.grein@emea.eu.int
MRL assessments in the EU in the context of Council Regulation (EEC) No Substance Regulation amending Annex of Regulation 2377/90
Regs 1286/2000 ; 77/2002; 75/2005; 1518/2005
Regs 3093/92; 1798/96; 1191/98; 1646/2004
Aloe vera gel and whole leaf extract of Annex II
Aloe vera Aloes, Barbados and Capae
Aminoethanol glucoronate) Aminoethyl dihydrogenphosphate [2-
Regs 3093/92; 1430/94; 1742/96; 1916/98; 1836/97; 2395/99; 1646/2004
Substance Regulation amending Annex of Regulation 2377/90 Anisi stellati fructus, standardised
extracts and preparations thereof Apis mellifica Aristolochia spp. And preparations
Substance Regulation amending Annex of Regulation 2377/90
Annex II proposal – Rejected by the Commission
Substance Regulation amending Annex of Regulation 2377/90
meat) Cefazolin (bovine, ovine and caprine
Cefquinome (bovine, porcine, Equidae) Annex I
Regs 895/93; 282/96; 954/99; 1931/99; 2145/2003
Regs 1837/97; 804/99, 1752/2002; 1231/2006
Substance Regulation amending Annex of Regulation 2377/90 Cimicifugaeracemosae rhizoma Cinchonae cortex, standardised extracts Annex II
and preparations thereof Cinnamomi cassiae aetheroleum Cinnamomi cassiae cortex, standardised Annex II
extracts and preparations thereof Cinnamomi ceylanici aetheroleum
standardised extracts and preparations thereof Citri aetheroleum
extracts and preparations thereof Convallaria majalis Substance Regulation amending Annex of Regulation 2377/90
Regs 954/99 ; 77/2002; 869/2002; 1029/2003; 1490/03; 1646/2004
Regs 1442/95; 1837/97; 121/98; 1942/99; 953/99; 1942/99; 1181/2002
Regs 1942/99; 1960/2000; 1815/2001; 2162/2001; 1646/2004
Regs 1441/95; 749/97; 1837/97; 1646/2004
Regs 1311/96; 749/97, 997/99; 2908/2000; 1181/2002
Regs 1140/96; 1960/2000; 1530/2002; 6/2006
Substance Regulation amending Annex of Regulation 2377/90
Regs 1430/94; 270/97;1836/97; 2728/99; 1478/2001
Regs 2901/93; 2728/98; 2593/99; 1181/2002
hexanediol] Ethylenediaminetetraacetic acid and
Annex II proposal – Rejected by the Commission
Regs. 675/92; 1441/95; 1837/97; 1646/2004
Regs 675/92; 1441/95; 1837/97; 1646/2004
Regs 2703/94; 613/98; 1942/99; 2385/99; 1322/2001; 1181/2002
Regs 895/93; 1798/96; 1000/98; 2385/99; 1055/2006
Regs 2584/2001; 665/2003; 739/2003; 1911/2005
Substance Regulation amending Annex of Regulation 2377/90
Follicle Stimulating Hormone (natural Annex II
FSH from all species and their synthetic analogues) Formaldehyde
Frangulae cortex, standardised extracts Annex II
and preparations thereofFumagillin No
Gentianae radix, standardised extracts Annex II
and preparations thereof Ginkgo biloba
(natural HCG and its synthetic analogues) Human menopausal urinary
gonadotrophin Humic acid and its sodium salt
Substance Regulation amending Annex of Regulation 2377/90
Iodine and iodine inorganic compounds Annex II
including: – Sodium and potassium – iodide – Sodium and potassium – iodate – Iodophors Iodine organic compounds
– Iodoform – Polyvinylpyrrolidine – iodine Iron ammonium citrate
Regs 675/92; 2901/93; 716/97; 2728/98; 869/2005
No recommendation for final Regs 282/96; 953/99; 2338/2000 MRLs
Substance Regulation amending Annex of Regulation 2377/90
Luteinizing Hormone (natural LH from Annex II
all species and their synthetic analogues) Lysine
Substance Regulation amending Annex of Regulation 2377/90
Regs 1569/98; 2393/99; 1274/2001; 1530/2002
Menthae arventisaetheroleum
viscosity including microcrystalline waxes, approximately C10-C60; aliphatic, branched aliphatic and salicyclic compounds Monothioglycerol
Reg. 997/99; 1322/2001; 1851/2004; 1356/2005
Regs 2703/94; 748/97; 613/98; 1942/99; 1553/2001; 75/2005
Regs 1850/97; 804/99; 807/2001; 546/2004
Substance Regulation amending Annex of Regulation 2377/90
Regs 675/92; 1441/95; 1837/97; 1646/2004
Oxidation products of terebinthinae
Regs 804/99; 807/2001; 739/2003; 546/2004; 1356/2005
Regs 997/99; 2338/2000; 1181/2002; 1646/2004
Regs 1311/96; 2034/96; 121/98; 2757/99; 1148/2005
Substance Regulation amending Annex of Regulation 2377/90
Regs 2385/99; 2391/2000; 807/2001; 1299/2005
Piceae turiones recentes extractum
Polyethylene glycol stearates with 8-40 Annex II
oxyethylene units Polyethylene glycol-15-hydroxystearate Annex II
Polyethylene glycol-7-glyceryl-cocoate Annex II
Polyethylene glycols (molecular weight Annex II
ranging from 200 to 10.000) Polymixin B sulphate
Polyoxyethylene sorbitan monolaurate Annex II (E-number 432)
(polysorbate 20) Polyoxyethylene sorbitan monooleate Annex II (E-number 433)
monopalmitate (polysorbate 40) Polyoxyethylene sorbitan monostearate Annex II (E-number 435)
(polysorbate 60) Polyoxyethylene sorbitan tristearate
(polysorbate 65) Polyoxyl castor oil with 30 to 40
oxyethylene units Polyoxyl hydrogenated castor oil with
40 to 60 oxyethylene units (Fatty acid polyethylene glycol ester) Polysulphated glycosaminoglycan
Substance Regulation amending Annex of Regulation 2377/90
Propyleneglycol alginate (Propane-1,2- Annex II (E-number 405)
Sodium 2-methyl-2-phenoxypropanoate Annex II
Substance Regulation amending Annex of Regulation 2377/90 Substance Regulation amending Annex of Regulation 2377/90
mono- and di-basic salt of sodium, potassium and calcium Tau-fluvalinate
Terebinthinae aetheroleum rectificatum Annex II
Regs 3093/92; 1311/96; 1000/98; 1646/2004
Regs 955/94; 1102/95; 1917/98; 2338/2000; 2391/2000; 1274/2001; 1181/2002
Regs 1916/98; 2593/99; 2908/2000; 2232/2004; 205/2006
Substance Regulation amending Annex of Regulation 2377/90
Regs 3093/92; 1442/95; 1838/97; 1960/2000; 1181/2002
STABILIMENTO CHIMICO FARMACEUTICO MILITARE Informazioni per l’acquisto di Mexiletina Cloridrato 200 mg capsule rigide La fornitura del farmaco è subordinata all’invio contemporaneo al seguente indirizzo e-mail: pr o d uz io ne . or al i@ f a r m ac eu tic om il it ar e .it , o pp u r e , in al ter na tiva , a l n . FA X 055 451866, dei 1) Richiesta del medico ai sensi de